Treatment for women with asymptomatic heart failure after preeclampsia
Timely Recovery After Subclinical Heart Failure (TREASURE Trial)
PHASE4 · Academisch Ziekenhuis Maastricht · NCT06341101
This study tests whether a heart medication called Perindopril can help women with heart issues after preeclampsia feel better compared to standard care.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 130 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Academisch Ziekenhuis Maastricht (other) |
| Locations | 1 site (Maastricht, Limburg) |
| Trial ID | NCT06341101 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial evaluates the effectiveness of ACE inhibitors, specifically Perindopril, compared to standard care in reversing asymptomatic heart failure and diastolic dysfunction in women with a history of preeclampsia. Over a two-year open-label treatment period, the study will assess various outcomes including structural and functional myocardial improvement, progression to symptomatic heart failure, cardiovascular performance, and quality of life. Participants will be randomly assigned to either the medication group or the usual care group after a thorough cardiovascular assessment.
Who should consider this trial
Good fit: Ideal candidates are premenopausal women aged 18 and older with a history of preeclamptic pregnancy and subclinical heart failure or diastolic dysfunction.
Not a fit: Patients who are currently pregnant, breastfeeding, or have pre-existing conditions such as diabetes or kidney failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve heart function and quality of life for women with a history of preeclampsia who are at risk for heart failure.
How similar studies have performed: Other studies have shown promise in using ACE inhibitors for heart failure management, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All women who visit Maastricht Univeristy Medical Center+ for Cardiovascular screening with subclinical/asymptomatic heart failure (HF stage-B) and/or diastolic dysfunction; * Aged 18 years and older; * Premenopausal women with a history of preeclamptic pregnancy and premenopausal women with a history of normal pregnancy; * Between 0.5 and 30 years postpartum; Exclusion Criteria: * Intention to pursue pregnancy within 2 years; * Already using antihypertensive medication; * Suffering diabetes mellitus, kidney failure (GFR\<60 ml/min/1.73m2), pre-existent auto-immune disease and/or liver insufficiency; * Breastfeeding during participation; * Previous angio-edema
Where this trial is running
Maastricht, Limburg
- AZMaastricht — Maastricht, Limburg, Netherlands (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Heart Failure, Diastolic Dysfunction, Pre-Eclampsia, hypertension, heart failure, treatment